New preprints, nonprofit research updates, and science releases on the type 1 diabetes cure, surfaced early and labeled honestly. Preprints are the earliest data: small studies, not yet peer reviewed, and exactly where breakthroughs first show up.
Preprints are not peer reviewed and early findings often change. This lane is for the earliest research signal, clearly labeled. It is information, not medical advice.
Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The mome…
Read the sourceFinerenone is the First Therapy Approved in 30 Years for Kidney Disease and T1D Today, the U.S. Food and Drug Administration (FDA) approved finerenone (brand name Kerendia) to reduce urinary albumin-to-creatinine ratio (UACR) in adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D). UACR is a …
Read the sourceNew Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type …
Read the source